|
SK44894A3
(en)
*
|
1991-10-18 |
1995-04-12 |
Monsanto Co |
Trisubstituted aromatic compounds, method of their preparation and fungicidal agents
|
|
SE9703407D0
(sv)
*
|
1997-09-19 |
1997-09-19 |
Astra Ab |
New use
|
|
SE9802073D0
(sv)
|
1998-06-11 |
1998-06-11 |
Astra Ab |
New use
|
|
GB9825554D0
(en)
*
|
1998-11-20 |
1999-01-13 |
Smithkline Beecham Spa |
Novel Compounds
|
|
US7037922B1
(en)
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
EP1165542B1
(en)
|
1999-03-29 |
2003-08-20 |
Neurogen Corporation |
4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
|
|
AU4802500A
(en)
|
1999-04-26 |
2000-11-10 |
Neurogen Corporation |
2-aminoquinolinecarboxamides: neurokinin receptor ligands
|
|
JP2004525184A
(ja)
*
|
2001-04-11 |
2004-08-19 |
グラクソスミスクライン・ソシエタ・ペル・アチオニ |
Ｎｋ−３およびｎｋ−２受容体アンタゴニストとしての３−置換キノリン−４−カルボキサミド誘導体
|
|
AU2002259147A1
(en)
*
|
2001-05-08 |
2002-11-18 |
Schering Corporation |
Use of neurokinin receptor antagonists to treat androgen-dependent diseases
|
|
PT2246360E
(pt)
|
2003-01-28 |
2012-08-31 |
Ironwood Pharmaceuticals Inc |
Composições para o tratamento de desordens gastrointestinais
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
GB0303086D0
(en)
|
2003-02-11 |
2003-03-19 |
Merck Sharp & Dohme |
New compounds
|
|
GB0419192D0
(en)
|
2004-08-27 |
2004-09-29 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
MX2007005590A
(es)
*
|
2004-11-09 |
2007-05-24 |
Smithkline Beecham Corp |
Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
|
|
GB0425077D0
(en)
*
|
2004-11-12 |
2004-12-15 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0515580D0
(en)
|
2005-07-29 |
2005-09-07 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
EP1915361A1
(en)
*
|
2005-08-11 |
2008-04-30 |
AstraZeneca AB |
Alkylpyridyl quinolines as nk3 receptor modulators
|
|
AR057130A1
(es)
|
2005-09-21 |
2007-11-14 |
Astrazeneca Ab |
Quinolinas de alquilsulfoxido y una composicion farmaceutica
|
|
TW200804288A
(en)
|
2005-12-12 |
2008-01-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
EP2195287A1
(en)
*
|
2007-09-28 |
2010-06-16 |
GlaxoSmithKline LLC |
Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
|
|
MX2010003442A
(es)
*
|
2007-09-28 |
2010-04-21 |
Glaxosmithkline Llc |
Compuesto inhibidor de fosforilasa de glicogeno y composicion farmaceutica del mismo.
|
|
WO2009149279A2
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
CA2730603C
(en)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
EP3351248B1
(en)
|
2008-12-31 |
2021-06-09 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
EP2887964B1
(en)
|
2012-08-21 |
2019-07-03 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
RU2675364C2
(ru)
|
2013-04-12 |
2018-12-19 |
Арделикс, Инк |
Nhe3-связывающие соединения и способы ингибирования транспорта фосфатов
|
|
CA2909752A1
(en)
|
2013-04-19 |
2014-10-23 |
Astrazeneca Ab |
A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
|
|
AU2014274812B2
(en)
|
2013-06-05 |
2018-09-27 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
EA201991676A1
(ru)
|
2017-01-09 |
2020-01-30 |
Арделикс, Инк. |
Ингибиторы nhe-опосредованного антипорта
|
|
WO2018129552A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds useful for treating gastrointestinal tract disorders
|